- Home
- WINA vs CRVS Comparison
WINA vs CRVS Comparison
Compare WINA & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WINA | CRVS |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2006 | 2016 |
Fundamental Metrics
Financial Performance| Metric | WINA | CRVS |
|---|---|---|
| Price | $428.65 | $15.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 61.2K | ★ 1.1M |
| Earning Date | 06-02-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.06% | N/A |
| EPS Growth | ★ 3.76 | N/A |
| EPS | ★ 11.30 | N/A |
| Revenue | ★ $86,055,700.00 | N/A |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $6.03 | N/A |
| P/E Ratio | $40.02 | ★ N/A |
| Revenue Growth | ★ 5.86 | N/A |
| 52 Week Low | $295.79 | $2.54 |
| 52 Week High | $526.81 | $26.95 |
Technical Indicators
Market Signals| Indicator | WINA | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 41.40 | 41.19 |
| Support Level | $406.77 | $6.65 |
| Resistance Level | $447.66 | $18.73 |
| Average True Range (ATR) | 23.42 | 1.02 |
| MACD | -1.62 | -0.48 |
| Stochastic Oscillator | 17.24 | 11.94 |
Price Performance
Historical ComparisonAbout WINA Winmark Corporation
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).